COVID-19 and HSCT (Hematopoietic stem cell transplant). Issue 3 (September 2022)

• Record Type: Journal Article
• Authors: Strasfeld, Lynne
• Is Part Of: Baillière's best practice and research in clinical haematology. Volume 35:Issue 3(2022)
• Publication Date: 2022-09
• Subjects: COVID-19 -- SARS-CoV-2 -- Hematopoietic stem cell transplant -- HSCT -- Prevention -- Treatment; Hematology -- Periodicals; Blood -- Periodicals; Hematologic Diseases -- Periodicals; Electronic journals; 616
• DOI: 10.1016/j.beha.2022.101399
• Languages: English
• ISSNs: 1521-6926

Abstract

Abstract: HSCT recipients are at increased risk for COVID-19-associated morbidity and mortality. Early treatment of symptomatic SARS-CoV-2 infection is an important means to decreasing risk for severe disease and death. While some HSCT recipients, particularly those who are early post-transplant and severely immunosuppressed, may have diminished response to COVID-19 vaccines, the benefits of vaccination are uncontested. Public health, healthcare facility and individual level approaches are all necessary to mitigate risk for infection in this vulnerable population.